Edition:
United States

People: Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

3.56USD
11:21am EDT
Change (% chg)

$0.06 (+1.71%)
Prev Close
$3.50
Open
$3.47
Day's High
$3.58
Day's Low
$3.44
Volume
2,446
Avg. Vol
74,529
52-wk High
$14.52
52-wk Low
$3.20

Furey, John 

Mr. John P. Furey is re designated as Non-Executive Independent Director of the company effective from July 5, 2018. He is a Chief Operating Officer at Spark Therapeutics, Inc. He is responsible for global commercial operations, medical affairs, technology development and technical operations. He has 25 years of experience in developing and implementing operational strategies and leading commercial and technical teams. Prior to joining Spark Therapeutics, John was senior vice president and head of global operations for Baxalta, where he directed manufacturing, quality, engineering, and process development. He actively managed a $2.5 billion production budget across Baxalta’s global network and led a first-in-class supply chain organization for rare diseases. John led the team that coordinated and delivered the successful establishment of Baxalta through a spin out from Baxter and led the Baxter Vaccine inline business to realize significant top line and bottom line growth. He also spent two years in China as general manager of Pfizer’s vaccine business unit following a role with responsibility for global pricing and reimbursement at Pfizer Vaccines. In these roles, John gained extensive experience in pipeline development and global product launches. Earlier in his career, he held both commercial and operations positions of increasing scope and responsibility with Pfizer and Wyeth Pharmaceuticals. John has an executive M.B.A. from St. Joseph’s University, Philadelphia, a B.S. from Trinity College, Dublin, and a diploma in Environmental Health from the Dublin Institute of Technology.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --